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Abstract
Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignan-
cies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients 
with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CAR-T constructs are in research for both 
hematological and non-hematological diseases. Most of the patients receiving CAR-T therapy will develop fever at some 
point after infusion, mainly due to cytokine release syndrome (CRS). The onset of CRS is often indistinguishable from an 
infection, which makes management of these patients challenging. In addition to the lymphodepleting chemotherapy and 
CAR T cells, the treatment of complications with corticosteroids and/or tocilizumab increases the risk of infection in these 
patients. Data regarding incidence, risk factors and prevention of infections in patients receiving CAR-T cell therapy are 
scarce. To assist in patient care, a multidisciplinary team from hospitals designated by the Spanish Ministry of Health to 
perform CAR-T therapy prepared these recommendations. We reviewed the literature on the incidence, risk factors, and 
management of infections in adult and pediatric patients receiving CAR-T cell treatment. Recommendations cover different 
areas: monitoring and treatment of hypogammaglobulinemia, prevention, prophylaxis, and management of bacterial, viral, 
and fungal infections as well as vaccination prior and after CAR-T cell therapy.
Keywords Chimeric antigen receptor · Diffuse large B-cell lymphoma · B-cell acute lymphoblastic leukemia · Bacterial 
infections · Viral infections · Fungal infections
Introduction
Chimeric antigen receptor (CAR) T-cell therapy is one of 
the most promising emerging treatments for hematologic 
malignancies [1, 2]. Although there are several therapeutic 
targets under development, CD19 is the most widely used 
antigen for the treatment of B-cell malignancies. Recently, 
two CAR T products have been approved for the treatment 
of lymphoid malignancies, axicabtagene ciloleucel (axi-cel) 
or  Yescarta® (Gilead Inc., USA) for the treatment of diffuse 
large B-cell lymphoma (DLBCL) and primary mediastinal 
B-cell lymphoma (PMBCL), and tisagenlecleucel (tisa-cel) 
or  Kymriah® (Novartis Inc., Basel, Switzerland) for the 
treatment of DLBCL and B-cell acute lymphoblastic leu-
kemia (B-ALL).
Most of the patients receiving CAR T therapy will 
develop fever after infusion [3], mainly due to cytokine 
release syndrome (CRS), a systemic inflammatory condition 
mediated by CAR T-cells. This syndrome is often indistin-
guishable from an infection as it usually includes tachycar-
dia, tachypnea and hypotension [4]. CRS is produced by 
endothelial activation and overproduction of inflammatory 
cytokines such as interferon γ (IFN-γ), interleukin 6 (IL-6) 
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and tumor necrosis alpha (TNF-α) [5]. Increased plasma 
levels of these cytokines have also been observed in sepsis 
[6]. Some studies have looked into the cytokine results in 
both CRS and infection trying to find a different biomarker 
profile. One of these studies did not find any differences in 
the cytokine profile of these two groups of patients [7]. How-
ever, another study was able to develop a prediction model 
including three cytokines (IL-8, IL-1β and IFN-γ) to detect 
life-threatening infections [8]. In any case, more research 
is needed to identify specific biomarkers differentiating the 
two clinical settings.
Since only a limited number of patients have been treated 
with CAR T-cell therapies, there are scarce data on inci-
dence, risk factors and preventive strategies [8, 9] in these 
patients. We present herein recommendations on the man-
agement of infections for patients receiving CAR T cells.
Methodology
A multidisciplinary team from the hospitals designated by 
the Spanish Ministry of Health to deliver CAR T-cell ther-
apy contributed to this set of recommendations for preven-
tion and management of infections. To implement clinical 
decisions, these recommendations should always be con-
sidered together with the underlying disease, previous treat-
ments and local epidemiology.
The preparation and writing of this manuscript involved 
hematologists, infectious diseases specialists and pedia-
tricians. We performed a systematic literature search in 
PubMed, using the search filters “CAR T AND infection”, 
“CAR T AND follow-up”, “CAR T AND prophylaxis”, 
“CAR T AND hypogammaglobulinemia” and “CAR T AND 
vaccines”. The final document was reviewed and approved 
by all authors. Table 1 is a summary of the most important 
recommendations of this document.
Incidence and risk factors
Incidence
Data regarding the incidence of infections in these patients 
are scarce, and this may vary depending on the underlying 
disease and the CAR T construct. The reported incidence 
of any infection in patients treated with tisa-cel for B-cell 
precursor ALL [9] and DLBCL is 65% and 54%, respec-
tively. Serious infections (grade 3 or higher) occurred in 
44% and 32% of ALL and DLBCL patients, respectively, 
most of them occurring within the first 8 weeks after CAR 
T-cell infusion. Regarding axi-cel, 35% and 38% of patients 
with relapsed/refractory DLBCL included in the ZUMA-1 
trial developed febrile neutropenia and infections, respec-
tively [10]; 25% of these infections were grade 3 or higher. 
Most patients had an infection without microbiological 
isolation, followed by bacterial and viral infections, mostly 
with respiratory tract involvement. Logue et al. described 
a similar incidence of infections, 37% in the first 30 days, 
being Clostridioides difficile colitis the most frequent (14% 
of all patients) [11]. Recently, Wudhikarn et al. reported 
in patients with DLBCL a cumulative incidence of 63% of 
infections at 1 year [12].
Finally, Cordeiro et al. [13] reported an infection density 
of 0.55 infections/100 days at risk (2.08/patient year) within 
the first 90 days after CAR T-cell infusion in adult patients. 
Eighty percent of them were treated in the outpatient set-
ting. Twenty-four percent of these events had a microbio-
logical etiology, mainly bacterial (60%), viral (31%) (mostly 
respiratory viruses) and fungal (9%) infections. Moreover, 
infection was the main cause of non-relapse mortality (8/12 
cases, 66.7%) in DLBCL patients treated with axi-cel in the 
standard-of-care setting [14].
Risk factors
Patient-, disease- and construct-related factors as well as 
treatment-related variables can increase the risk of infec-
tion [7, 12, 15]. Age has been identified as a risk factor for 
developing CRS and neurological events after CAR T-cell 
therapy [16], but it has not been clearly associated with an 
increased risk of infection. Baseline disease (being higher 
in ALL than in DLBCL), type and number of previous anti-
tumor regimens have also been identified as potential risk 
factors for the development of infections. The dose of CAR 
T-lymphocytes [15], as well as type and intensity of lym-
phodepleting chemotherapy can also contribute to the devel-
opment of infections after therapy [15]. Neutropenia, which 
has been described in up to 80% of the patients within the 
first month after infusion [17] can also increase the risk of 
infection in these patients, especially in those with long-term 
persisting cytopenias [13, 17, 18].
CRS itself through endothelial damage and its treatment 
with tocilizumab and/or corticosteroids can favor and/or 
complicate some infections [7, 15]. Tocilizumab has been 
associated with increased risk of infection in patients with 
rheumatoid arthritis [19]. In patients receiving CAR T cells, 
its use has also been associated with a higher risk of infec-
tion. Since tocilizumab is used in most cases of severe CRS 
it is difficult to differentiate between CRS itself and its treat-
ment as the direct cause of infections. In patients with mild 
CRS (grade 1) the use of tocilizumab was not associated 
with increased risk of infection in a recent study [20]. In 
some cases, anakinra (IL-1R inhibitor) has been used for 
the treatment of CRS and neurotoxicity [21]; this drug could 
also potentially increase the risk of infection [22, 23], but 
clinical experience in these patients is scarce.
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Finally, CAR T therapy causes a variable-length B-cell 
aplasia (while circulating CAR T persists, which varies 
from a few days to several years) [24, 25] and a progressive 
secondary hypogammaglobulinemia, exposing them to life-
threatening infections, especially in pediatric patients with 
ALL [26].
In summary, risk factors for bacterial, fungal, and viral 
infections are neutropenia, B-cell aplasia/hypogammaglobu-
linemia and impaired cellular immunity, along with the use 
of tocilizumab and/or corticosteroids for the treatment of 
CRS and/or neurotoxicity (Fig. 1) [7, 15, 26].
Hypogammaglobulinemia
In the B-cell ALL setting, a study with 43 pediatric patients 
and young adults showed a 90% prolonged B-cell aplasia 
after therapy [27].
In the ELIANA trial, all the patients who responded 
developed B-cell aplasia and most of them received replace-
ment therapy with immunoglobulins according to the local 
policy. The median recovery time had not yet been reached, 
with a probability of 83% of maintaining B-cell aplasia at 
6 months after infusion [18]. A single-center study, con-
ducted at the University of Pennsylvania including 28 
patients, monitored the levels of immunoglobulins after CAR 
T-cell therapy in 12 ALL patients. Two of these patients 
received replacement treatment from 12 to 22 months after 
the infusion due to recurrent sinopulmonary infections. The 
remaining ten patients did not receive substitute treatment, 
and recovered IgG count at a median of 18 months after the 
infusion [28]. Seventy-five percent of the patients diagnosed 
with non-Hodgkin lymphoma included in the ZUMA-1 [10] 
trial achieving disease response after axi-cel showed restored 
B-lymphocyte count 24 months after the infusion, and recov-
ery began in some cases at 9 months. Thirty-three (31%) of 
the 108 infused patients received replacement therapy with 
Ig, including 17 (44%) of the 39 patients with longer lasting 
responses [10, 29].
In conclusion, the incidence and severity of hypogamma-
globulinemia varies across studies, being higher in patients 
with ALL. Furthermore, a recent study confirmed the per-
sistence of circulating CD19 negative plasma cells in a small 
series of patients with ALL and chronic lymphocytic leu-
kemia (CLL); the humoral response in this case could be 
long-lasting despite treatment with CAR T [30].
Management of hypogammaglobulinemia
Although there are some published recommendations [25, 
31], there is no clear consensus on immunoglobulin replace-
ment therapy in patients who have received CAR T-cell 
therapy. The subset of patients, timepoints and schedule are 
the most frequently unresolved questions. Therefore, our rec-
ommendations are based on clinical experience from other 
neoplastic diseases (such as CLL or multiple myeloma) and 
hematopoietic stem cell transplantation (HSCT). In children, 
especially when they are under 10 years of age, the protocols 
of agammaglobulinemia are recommended [32].
Recommendations in the adult population
1. Monitoring
  All patients should have a baseline assessment of 
lymphocyte subsets and immunoglobulin levels prior 
to lymphodepleting chemotherapy. After the infusion, 
the time points for assessment of lymphocyte subsets 
(CD4+) and immunoglobulins should be monitored:
• Monthly until the 6th month after infusion.
• After the first 6 months, it will be done according to 
clinical criteria. In general, among those patients with-
out hypogammaglobulinemia, immunoglobulin levels 
should be assessed at least twice a year (and immuno-
globulin subclasses monitored annually).
Fig. 1  Risk factors for infection in patients receiving CAR T cells
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2. Replacement therapy
• An individual IgG level has been proposed, which 
should be adapted to each patient over time, being the 
one that improves their clinical status and reduces the 
percentage of infections [33].
• Substitution therapy should be considered in two other 
situations:
o Deficit of some immunoglobulin subclass.
o Absence of seroconversion after vaccination of teta-
nus, diphtheria or pneumococcus.
• In overweight patients (BMI ≥ 30  kg/m2 or if real 
weight > 20% of the ideal weight), the dose should 
be adjusted to the ideal adjusted weight according to 
the following formula: ideal adjusted weight = ideal 
weight + 0.4 [real weight (kg) − ideal weight].
• If the patient has a selective IgA deficit, even though 
adverse events due to specific anti-IgA are less frequent 
than previously thought [34], priority should be given 
to products with the lowest possible amount of IgA or 
to subcutaneous administration [35].
• If substitution is necessary, 400–600  mg/kg every 
3–4 weeks [36] is accepted as the starting dose, aim-
ing to reach an IgG trough above 400 mg/dL in adults.
• If a patient develops frequent respiratory infections, 
despite monthly replacements, the physician should 
consider raising the dose, reducing the administration 
interval or switching to subcutaneous formulations.
Recommendations in pediatric population
• Replacement therapy should start ~ 1 month after CAR 
T infusion in all patients [24, 25].
• The recommended replacement dose is 0.5  g/kg/
monthly [25, 37, 38], aiming to reach the normal range 
for the child’s age.
• In children, it may be advisable to achieve higher 
IgG trough values (800 mg/dL) [38], especially under 
10 years of age and when there are associated risk fac-
tors such as baseline pulmonary pathology, history of 
total body irradiation or added immunosuppression by 
chronic graft versus host disease.
• Replacement therapy should last as long as B-cell 
aplasia. If there is a persistent low IgA or IgM value 
replacement therapy should be maintained.
• Once there is B-cell recovery, the decision to stop 
immunoglobulin replacement should be evaluated on 
a case-by-case basis.
Bacterial infections
The incidence of bacterial infection described in patients 
receiving CAR T therapy ranges from 10 to 43% [7, 15, 18, 
39]. This incidence is possibly higher taking into account 
that some bacterial infections could be underdiagnosed in 
the context of CRS. Incidence of grade 4 and 5 bacterial 
infections < 6% [7, 18, 40].
Prevention/prophylaxis and management 
of bacterial infection
Our general recommendations for the prevention of bacte-
rial infection in these patients are:
• Patients with an active, uncontrolled infection should 
not start treatment with CAR T therapy until the infec-
tion has resolved. This includes both the lymphodeplet-
ing chemotherapy and the CAR T-cell infusion.
• Antibacterial prophylaxis is not recommended.
• If the patient develops fever or infectious symptoms, 
even if CRS is suspected, microbiological samples 
should be collected and empiric antibiotic treatment 
initiated according to the local protocol. The empiric 
antibiotic therapy should take into account the individ-
ual risk of the patient and the local antibiotic resistance 
profile, always including Pseudomonas aeruginosa.
• The clinical situation should be reassessed 48 h after 
the onset of fever. If there is no sign of active infec-
tion, the cultures are negative, the diagnosis of CRS is 
highly probable and the patient is afebrile or stable, the 
withdrawal of the antibiotic should be considered.
• There are no differences regarding prophylaxis and 




Herpes simplex virus (HSV) and VZV In European countries, 
the seroprevalence of HSV type 1 is around 80% in adults 
[41]. Hence, reactivation after immunosuppressive therapy 
in hematological patients is very frequent in the absence of 
prophylaxis.
There are no specific data on the incidence of compli-
cations associated with HSV after treatment with CAR T. 
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It should be noted, however, that most patients received 
prophylaxis with acyclovir or valacyclovir [7].
Regarding varicella zoster virus (VZV) infection, its 
incidence in CAR T recipients is also unknown. Patients 
receiving other immunosuppressive therapies, such as allo-
geneic HSCT, carry a high risk of developing this infection 
(15–50% after 5 years of treatment/transplantation). Note-
worthy, a case of early reactivation has been described in a 
patient who did not receive acyclovir prophylaxis [15].
Cytomegalovirus (CMV) In western European countries the 
CMV-positive adult population is around 70%. Two stud-
ies [7, 15] have reported the incidence of CMV infection/
disease in patients treated with CAR T. Among the 186 
patients included in both studies, two presented a reactiva-
tion of the virus detected by plasma PCR and one patient 
had a CMV pneumonia, diagnosed between days 29 and 90 
post-infusion.
There are no published data on the monitoring of viremia 
or the use of prophylaxis in this context.
Epstein–Barr virus (EBV) Only one study [15] including 
133 adult patients receiving CAR T-cell therapy for differ-
ent refractory or relapsed B-cell malignancies described the 
incidence of EBV infection in this context. A single patient, 
who developed CRS grade 4, presented a positive PCR in 
both plasma and cerebrospinal fluid.
Human herpesvirus 6 (HHV‑6) Its seroprevalence is very 
high in the general population (> 95%). At present, no study 
has provided data on the incidence of complications related 
to HHV-6 in this context.
Prevention/prophylaxis and management
• Acyclovir prophylaxis should be administered in patients 
with a positive baseline serology, from the start of lym-
phodepleting chemotherapy until a minimum of 60 to 
100 days after infusion (Table 1). Our recommendation 
is to maintain the prophylaxis up to + 100 days after infu-
sion, and even longer in subgroups of patients considered 
at high risk (history of recent allogeneic transplantation, 
adverse events related to CAR T cells that required ster-
oid/tocilizumab treatment…). In seronegative patients 
for HSV and VZV, prophylaxis is not necessary. When 
the serological status is unknown, prophylaxis should be 
used routinely.
• The monitoring of CMV and EBV DNAemia should only 
be carried out for academic purposes, the results should 
not determine the start of preemptive treatment. Simi-
larly, prevention strategies, such as letermovir or rituxi-
mab, do not seem justifiable at the present time.
• Neither directed prophylaxis nor routine monitoring of 
HHV-6 PCR seems to have any role in these patients.
• In the pediatric population who has previously undergone 
an HSCT, the recommendation is to monitor CMV, ade-
novirus, EBV and HHV-6 once or twice a week. If there 
is a positive CMV PCR result, treatment with ganciclovir 
or foscarnet should be initiated.
Hepatotropic viruses
Patients receiving B-cell-targeted therapy like rituximab 
are at a higher risk for hepatotropic viral reactivation [42]. 
Safety of CAR T-cell therapy in patients with chronic hepa-
titis B virus (HBV) or hepatitis C virus (HCV) infection is 
scarce, since most of the trials excluded patients with active, 
latent or past infections. A few cases of patients with very 
low or undetectable HBV and HCV viral load were suc-
cessfully treated with CAR T cells [43]. However, a fatal 
case of VHB reactivation was described in a patient carrying 
HBsAg who discontinued antiviral prophylaxis [44].
Screening for HBV, including HBV surface antigen 
(HBsAg), core antibody (anti-HBc) and surface antigen 
antibody (anti-HBs), together with HCV and HIV is man-
datory. If a patient is HBsAg positive or HBsAg negative but 
anti-HBc positive, an HBV DNA study should be performed, 
irrespective of anti-HBs [45–48]. Antiviral treatment with 
entecavir is recommended in HBsAg-positive patients or 
patients with detectable HBV DNA before starting CAR T 
cells and during at least 6–12 months after infusion [49–51]. 
The duration should be decided on a case-by-case basis. In 
anti-HBc positive patients, with negative HBsAg and HBV 
DNA, antiviral treatment or monitoring of HBV DNA every 
1–3 months can be performed [50]. Patients with hepatitis C 
infection should be considered for antiviral treatment taking 
into account the patient’s liver function and clinical situa-
tion [52].
It is also advisable to perform a hepatitis A screen-
ing, even though there are no specific data in this context. 
Regarding HDV, patients with anti-HBc antibodies should 
be screened with anti-HDV serology, and HDV RNA should 
be performed if antibodies are positive [49]. HEV virus is 
an enteric transmitted infection usually subclinical and 
self-limited. However, chronic disease has been reported in 
immunocompromised patients and treatment with ribavirin 
has been suggested in this setting [49]. If a patient experi-
ences acute liver test abnormalities during CAR T therapy, 
hepatotropic virus should be analyzed.
Human immunodeficiency virus (HIV)
Patients diagnosed with HIV infection were excluded from 
clinical trials [53], so data in this setting is scarce. The 
European Society for Blood and Marrow Transplantation 
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(EBMT) and the Joint Accreditation Committee of ISCT 
and EBMT (JACIE) practice recommendations have sug-
gested that pharmaceutical companies could manufacture 
CAR T cells for HIV-positive patients if the viral load was 
undetectable after anti-retroviral treatment [54]. The pub-
lished clinical experience is limited to three patients with 
HIV successfully treated with CAR T cells without addi-
tional toxicity [55, 56].
More data are needed to make specific recommendations 
in this setting. Currently, the decision to treat HIV patients 
should be assessed on a case-by-case basis taking into 
account the viral load and risk of opportunistic infections.
Community‑acquired respiratory viruses (CRV)
Infections of the upper and/or lower respiratory tract (URTI/
LRTI) by community respiratory viruses are one of the 
leading causes of morbidity and mortality worldwide with 
multiple direct and indirect deleterious effects, representing 
a huge economic burden for the health system [57]. Most 
viruses, including influenza, parainfluenza (PIV) and metap-
neumovirus (hMPV) have a seasonal predominance, from 
late autumn to mid spring. The PIV peaks in autumn and 
spring but is also frequent throughout the year.
The severity depends on the type of virus, the age of the 
patient, the previous immunosuppression and whether it is 
a primary infection or reinfection. The infections produced 
by these viruses are clinically indistinguishable from each 
other. Often, those produced by hMPV are presented in the 
form of co-infection with bacteria, fungi, and other CRVs, 
as well as CMV. These co-infections have a high mortality 
rate [58, 59].
A recently published risk scale developed in the setting 
of allo-HSCT recipients identified three separate risk groups 
(low, intermediate and high) with an increasing risk of pro-
gression to lower respiratory tract and mortality [60] Even 
though this risk scale, known as the “immunodeficiency 
score index” (ISI), was designed to predict these compli-
cations in patients with respiratory syncytial virus (RSV) 
infection, it has proven useful in other types such as influ-
enza, coronavirus and adenovirus [61–63]. The variables 
included in ISI are neutropenia (< 500/mm3), lymphopenia 
(< 200/mm3), age > 40 years, graft versus host disease, ster-
oid use, myeloablative chemotherapy, and allo-HSCT. How-
ever, this scale has not been validated in patients receiving 
CAR T-cells.
The incidence of CRV infections after anti-CD19 CAR 
T therapy in two studies [7, 15] was around 6% within the 
first 30 days, and rose to 28% within the first 6 months after 
infusion [7]. Several studies, carried out in other high-risk 
populations with increased risk, showed that the presence of 
hypogammaglobulinemia was associated with an increased 
risk of mortality due to CRV [64, 65].
The European Conference on Infections in Leukemia 
(ECIL) proposed some definitions based on the symptoms 
and PCR results to improve management strategies [66].
General prevention/prophylaxis and management 
of respiratory virus infection
• We recommend testing only patients with symptoms 
of URTI/LRTI, especially looking for the ones which 
have an antiviral treatment (influenza, RSV, ± PIV and 
hMPV). To avoid a delay in diagnosis and treatment, 
rapid detection techniques for influenza and RSV anti-
gens are a choice during the period of circulation of these 
viruses. However, given their lower sensitivity and speci-
ficity, multiplex PCR techniques in the same sample are 
advisable if rapid detection is negative.
• General precautions for preventing the transmission 
of CRV, including hand washing, personal protective 
equipment (gloves, gown and mask), and education to 
caregivers and patients should also be implemented in 
the CAR T setting. Health-care personnel and caregiv-
ers with symptoms of respiratory infection should avoid 
close contact with CAR T recipients.
Recommendations for influenza virus
• Influenza vaccination of CAR T recipients and close fam-
ily is recommended.
• Patients with confirmed influenza before the start of CAR 
T therapy should receive antiviral treatment and delay 
start of lymphodepleting chemotherapy at least 2 weeks 
or until resolution of symptoms.
• All patients with confirmed or probable influenza after 
CAR T infusion should receive treatment, regardless of 
the time elapsed since the infusion.
• The first-line treatment for influenza is oseltamivir. In 
severe cases of influenza, when the intestinal absorption 
of the drug is decreased (mucositis and/or diarrhea) and 
inhalation of zanamivir is not possible, intravenous per-
amivir or zanamivir could be alternatives.
• In patients with persistent symptoms, after ruling out 
oseltamivir resistance, treatment and isolation should be 
maintained until symptoms are resolved and/or PCR is 
negative.
Recommendations for respiratory syncytial virus (RSV)
• In patients with respiratory symptoms and a proven RSV 
infection before the start of CAR T therapy, it is advis-
able to start antiviral treatment and delay the start of 
lymphodepleting chemotherapy at least 2 weeks or until 
symptoms resolve.
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• In patients with LRTI who have received CAR T therapy 
within the previous 90 day and who present lymphope-
nia, neutropenia or hypogammaglobulinemia, ribavirin 
is recommended, orally or intravenously, in increasing 
doses up to a maximum of 30 mg/kg/day divided in three 
doses ± IVIG.
• Children under 2 years of age, especially those with a 
history of respiratory pathology, prophylaxis with mono-
clonal antibodies against RSV could be considered.
Recommendations for other CRV
• In the absence of effective agents against VPI [67–69] 
and hMPV [58, 59] treatment with ribavirin ± IVIG is 
advised in patients with one or more risk factors for pro-
gression to LTRI and in patients with UTRI. The possible 
toxicities of ribavirin, especially myelotoxicity, should be 
taken into account.
• There are currently no effective antiviral drugs available 
for enterovirus, rhinovirus, coronavirus and bocavirus. 
Therefore, recommendations in this setting are limited. 
Early identification and supportive treatment are impor-
tant, together with treatment of associated bacterial and/
or fungal infections.
Severe acute respiratory syndrome coronavirus 2 
(SARS‑CoV‑2)
In December 2019, a new virus named SARS-CoV-2 was 
identified in Wuhan, China [70]. The World Health Organi-
zation declared the SARS-CoV-2 outbreak a pandemic and 
reported on June 1, 2020 more than six million cases with 
371,166 deaths [71]. Three stages of the disease have been 
described: an early mild infection, followed by pulmonary 
damage and finally a systemic hyperinflammation [72]. High 
levels of pro-inflammatory cytokines and biomarkers includ-
ing IL-2, IL-6, IL-7, tumor necrosis-α or d-dimer have been 
identified in patients with more severe disease. For this rea-
son, some immunomodulatory agents including tocilizumab 
have been investigated as possible treatment for this disease 
[72].
Hematological patients with SARS-CoV-2 seem to harbor 
a dismal outcome [73–75]. Data about SARS-CoV-2 infec-
tion in patients receiving CAR T cells are very limited [73] 
and do not allow drawing definitive conclusions.
Several antiviral and immunomodulatory agents are 
currently under evaluation for the treatment of this infec-
tion [76, 77]. In patients with oxygen saturation lower than 
95%, dexamethasone for 10 days as well as remdesivir 
for 5 days is recommended in the last Infectious Disease 
Society of America (IDSA) guidelines [78]. Despite the 
lack of data in patients receiving CAR-T cells, it seems 
reasonable to take a similar approach in patients develop-
ing severe SARS-CoV-2.
During the SARS-CoV-2 pandemic, health-care systems 
suffered a high incidence of admissions due to this disease 
with overuse of intensive care units (ICU) in some cases. 
In this context, patient selection should be conducted care-
fully, while still allowing patients with good performance 
status and limited comorbidities to be considered for CAR 
T-cell therapy [79].
CAR T-cell treatment candidates should follow pre-
ventive measures such as strict hygiene procedures and 
social distancing [77, 79]. Moreover, symptoms of SARS-
CoV-2 infection should be assessed and screening of this 
infection with PCR should be made at relevant time points 
regardless of symptoms, including before apheresis, lym-
phodepleting chemotherapy and CAR T-cell infusion in all 
CAR-T cell candidates [79].
Other viruses
Adenovirus (HAdV)
There are no studies on the incidence of HAdV in patients 
treated with chemo-immunotherapy; however, it can cause 
serious problems in this population. It usually affects chil-
dren or young adults. In vivo or ex vivo T-cell depletion 
is the main risk factor for infection in this population [80, 
81] and severe lymphopenia (< 200/mm3) is the main risk 
factor for mortality [66].
Recommendations for HAdV 
• PCR monitoring is not routinely recommended in 
adults. In the pediatric population, it should be carried 
out one to two times per week. Early antiviral therapy 
with ribavirin is not recommended. Consider treatment 
with cidofovir in children, to avoid systemic disease 
[82, 83]. Brincidofovir is an alternative, but currently 
as a compassionate use and with possible adverse 
events such as gastrointestinal toxicity [84].
• In patients with URTI due to hAdV, measures such 
as isolation, close monitoring, and assessment of risk 
factors for progression to LTRI are recommended. In 
patients with severe LTRI and at least one risk factor, 
antiviral treatment with cidofovir for 2–3 weeks should 
be considered; thereafter, every 2 weeks until complete 
resolution. On the day of administration of cidofovir, 
remember to add hydration and oral probenecid. The 
use of brincidofovir is restricted to intolerance/toxicity 
to cidofovir [83].
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Polyomavirus (Polyomavirus hominis 1 and 2)
About 80% of the adult population is seropositive against the 
Polyomaviridae virus, including both pathogenic species: 
Polyomavirus BK (hemorrhagic cystitis) and Polyomavirus 
JC (progressive multifocal leukoencephalopathy). Anecdotal 
cases of BK infections and hemorrhagic cystitis have been 
described after CAR T-cell therapy [7, 15].
Taking into account the lack of conclusive data on the 
impact of reactivation, this possibility should always be 
suspected in case of the appearance of hemorrhagic cystitis 
(BK) or atypical neurological symptoms with a multifocal 
demyelination, especially when its presentation is late (JC).
Routine PCR monitoring in blood and/or urine for BK 
virus does not seem necessary in these patients.
Fungal infections
The incidence of invasive fungal infections (IFI) in adult 
patients with B-cell ALL, non-Hodgkin B-cell lymphoma 
or CLL treated with CAR T is globally between 5 and 
10% [7, 85]. In a study including 133 patients with several 
hematological malignancies receiving CAR T-cells, six of 
them (4.5%) developed eight episodes of IFI (5 for non-
filamentous fungi and 3 for filamentous) mostly within the 
first 28 days after infusion [15]. In this study, the prophylaxis 
consisted of fluconazole 400 mg/day when neutrophil count 
was below 500/mm3. There were no deaths associated with 
IFI.
Four of the 53 adult patients (7.5%) with B-cell ALL 
treated at MSKCC developed an IFI in the first 30 days 
after CAR T-cell infusion (1 yeast and 3 filamentous fungi 
lung infections [2 probable aspergillosis and 1 confirmed 
mucormycosis]). Of note, 79% of these patients received 
prophylaxis with micafungin at a dose of 100 mg/day [7]. 
The median number of days until IFI was 23. After day 30, 
1 IFI per filamentous fungus was documented. There were 
no deaths associated with IFI in this study.
Recently, the University of Pittsburg documented an inci-
dence of 3% (2/59) of IFI in their CAR T-cell recipients [86]. 
In the study of late complications by Cordeiro et al., [13], 
four fungal infections were recorded (2 Aspergillus spp., 1 
Candida spp. and 1 coccidioidomycosis).
Pre-test infection prevalence is a key factor when per-
forming diagnostic tests, including the determination of 
serum galactomannan (GM) and bronchoalveolar lavage 
(BAL) for detection of invasive aspergillosis (IA) [87]. The 
use of effective antifungal prophylaxis in high-risk hemato-
logic patients has shown to successfully reduce the incidence 
of IA [88]. Asymptomatic monitoring twice a week based on 
the determination of serum GM is unreliable, since the pre-
test probability of infection is very low and the possibility of 
false positive results due to other treatments is high (intra-
venous antibiotic treatment, platelet transfusion, nutritional 
supplements). The low rate of positive test prediction in this 
context limits its clinical utility and may involve unnecessary 
diagnostic and therapeutic efforts [89, 90]. It is important to 
analyze each case individually to establish the risk of IFI and 
implement early diagnostic measures.
In a survey of 52 pediatric and adult centers in the USA, 
87% administered antifungal prophylaxis to patients under-
going treatment with CAR T, the vast majority of them only 
against yeasts (92% with fluconazole). The duration of this 
prophylaxis was variable, but in most cases it was stopped 
at the time of neutrophil recovery [91]. Regarding Pneumo-
cystis jirovecii, all centers confirmed the use of prophylaxis, 
mostly with cotrimoxazole.
Prevention/prophylaxis and management of IFIs
• Routine serum GM monitoring is not recommended.
• Fluconazole 400 mg/24 h is advisable in the neutropenic 
phase after lymphodepleting chemotherapy.
• If the patient presents at least two of the following high 
risk factors, it is recommended to perform prophylaxis of 
filamentous fungi until neutrophil recovery (> 500/mm3):
o Four or more prior treatment lines [15].
o Neutropenia below 500/mm3 prior to infusion of 
CAR T.
o Dose of CAR T lymphocytes greater than 2 × 107/kg 
[7, 15].
o Previous IFI.
o Administration of tocilizumab and/or steroids.
  Prophylaxis can be carried out with posacona-
zole (tablets), nebulized liposomal amphotericin B 
or micafungin (Table 1). The duration of prophy-
laxis after neutrophil recovery should be decided 
on a case-by-case basis, taking into account the 
additional risk factors. Generally, we recommend 1 
month of antifungal prophylaxis after tocilizumab 
and/or steroids.
• There are no specific data in the pediatric population, but 
antifungal prophylaxis is widely recommended [3] in this 
setting with the appropriate dose adjustments (Table 1).
• Prophylaxis against Pneumocystis jirovecii is mandatory 
and includes trimethoprim sulfamethoxazole or inhaled 
pentamidine every 3–4 weeks. Trimethoprim sulfameth-
oxazole should be started 1 week before the cell infusion 
and maintained until the CD4+ count is greater than 200 
cel/mcL (stop during admission and restart once the cyto-
penias have recovered). Consider pentamidine in cases at 
risk of increasing the period of neutropenia (Table 1).
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Latent infections
Patients receiving immunosuppressive therapy should be 
screened for latent infections; with CAR T-cell therapy we 
take a similar approach. Patients coming from or often trave-
ling to endemic countries should be screened accordingly 
[92]. Specific recommendations are summarized in Table 2.
Vaccination of patients receiving CAR T
At present, there are no recommendations regarding the vac-
cine requirements of adult and pediatric patients treated with 
CAR T [93] therapy. There are no data on immunogenicity, 
efficacy, or safety of vaccine administration in this setting. 
The clinical and immunological status of these patients pre-
cludes the use of live and attenuated vaccines [94, 95].
As some patients treated with CAR T may have under-
gone HSCT (particularly patients with ALL) and may have 
not been vaccinated after this procedure, the model of vac-
cination after CAR T generally follows allo-HSCT vaccina-
tion schedules: the administration of vaccines is not recom-
mended until 3 months (in the case of inactivated vaccines) 
or 24 months (in the case of attenuated vaccines, only if 
no immunosuppression is active) after cell infusion [95]. It 
should be noted that during B-cell aplasia and administration 
of polyvalent immunoglobulin replacement therapy primary 
responses to vaccines may be very limited. Some memory is 
preserved for vaccines received pre-treatment, at the expense 
of long-lived plasma [30, 96].
Finally, it is recommended to enhance the immunization 
of immediate family members and health-care profession-
als [94].
Vaccination prior to CAR T therapy
Inactivated vaccines, due to the potential poor response, will 
be postponed to the post-CAR T stage, with the exception of:
• Influenza in epidemic season.
• Anti-pneumococcal conjugate, as patients with B-cell 
ALL have a high risk of invasive pneumococcal infec-
tion.
• HBV, especially in susceptible patients with high risk of 
infection or reactivation, and in areas of high prevalence 
of this infection.
• All house contacts of patients should be immunized 
against influenza. Also those susceptible to varicella 
or measles should be vaccinated. In case of vaccination 
against rotavirus (only in those younger than 7 months), 
they cannot be in contact with the patient for the follow-
ing 4 weeks.
Vaccination after CAR T therapy
• After CAR T therapy and during the B-cell depletion 
phase, live or attenuated vaccines should not be admin-
istered due to the risk of reactivation of the vaccine 
strain [97]. Postpone revaccination until the patients have 
recovered from B-cell aplasia.
• Regarding inactivated vaccines, and assessing the pos-
sible risk–benefit ratio [98], the influenza vaccine is rec-
ommended annually [93, 94], starting 30 days after CAR 
T infusion. There are no data confirming that two doses 
produce more immunogenicity than one.
• Specially important during B-cell aplasia, even though 
the effectiveness may be lower, are the pneumococcal 
conjugate vaccine (some patients have functional asple-
nia due to the previous treatments) and influenza (includ-
ing family members and cohabitants) [97]. Those vac-
cines should be repeated once when the B-cell aplasia is 
recovered.
Table 2  Screening of infectious diseases according to the geographical area:
CMV cytomegalovirus, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, HSV herpes simplex virus, IGRA 
interferon-gamma release assays, VZV varicella zoster virus, TG Toxoplasma gondii, TP Treponema pallidum
Central and South America Caribbean 
Islands





HIV, HBV, HCV, HSV, CMV, VZV, TG 
and TP serologies
Yes Yes Yes Yes Yes
IGRA Yes Yes Yes Yes Yes
Parasites in feces Yes Yes Yes Yes Yes
Strongyloides stercolaris serology Yes Yes Yes Yes Yes
Plasmodium spp. PCR Amazonian region Yes No Yes Yes
Trypanosoma cruzi serology Yes No No No No
Schistosoma mansoni serology Brasil and Venezuela Yes No Yes No
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• Immunoglobulin replacement therapy may reduce the 
immunogenicity of vaccines. Therefore, in case of vacci-
nation, it should be done between 1 week and 24 h before 
the next immunoglobulin infusion.
Once B-cell aplasia is resolved, the vaccination program 
should be started [97]. The immune response in this scenario 
is unknown. As in post-HSCT patients, combined vaccines 
could be used to improve immunological response [99–101].
Table 3  Vaccine program after CAR T-cell therapy in pediatric or adult patients with a previous HSCT
HA hepatitis A vaccine, HSCT hematopoietic stem cell transplantation, MACWY meningococcal A, C, W and Y vaccine, MB meningococcal B 
vaccine, MMR measles, mumps and rubella vaccine, HPV human papillomavirus vaccine, PN13 pneumococcal conjugated vaccine, PN23 pneu-
mococcal polysaccharide vaccine, VZ varicella vaccine
Antigens (vaccines) Time after HSCT Recommended interval between 
doses
Number of doses






















Meningococcus (MACWY) (MB) 12 months (dose 1)
18 months (dose 2)
12 months (12 and 18 months) 2






(PN23) PN23: 2 months after PN13 2
 12–24 months (dose 1)
 5 years after first dose of PN23 
(dose 2)
Hepatitis A (HA) 6 months (dose 1)
12 months (dose 2)
6 months 2
Influenza 4–6 months (influenza season) 1 month in first time vaccination of 
patients younger than 9 years
1 (2 in first-time vaccination 
of patients younger than 
9 years)
Papilloma virus (HPV) 12 months (dose 1)
13–14 months (dose 2)
18 months (dose 3)
1–2 months (between dose 1 and 2)
4 months (between dose 2 and 3)
3
Measles, mumps and rubella 
(MMR)
24 months (only if no immunosu-
pression or graft versus host dis-





Varicella (VZ) 24 months (only if no immunosu-
pression or graft versus host dis-
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In those who have not undergone HSCT, the vaccine 
program should include (if not administered before the cell 
infusion):
• Influenza in epidemic season.
• Anti-pneumococcal sequential vaccination: one dose of 
conjugated vaccine, followed by one dose of polysac-
charide vaccine a minimum of 8 weeks after. A second 
dose of polysaccharide vaccine should be administered 
a minimum of 5 years after the first dose.
• HBV, especially in susceptible patients with high risk of 
infection or reactivation, and in areas of high prevalence 
of this infection.
• Other inactivated vaccines may be indicated if other risk 
factors are present (i.e., hepatitis A vaccine in patients 
with chronic liver disease, Haemophilus influenzae b and 
meningococcal vaccines in asplenic patients, etc.)
In those who have undergone HSCT, the proposed vacci-
nation schedule is prepared according to the model of HSCT 
patients (Tables 3, 4).
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Table 4  Proposed calendar for 
post-CAR T patients who have 
undergone HSCT
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Visit Vaccines Observations




Visit 2 Hexavalent (2)
PN13 (2)
1 month after visit 1
Visit 3 Hexavalent (3)
PN13 (3)
HA (1)
1 month after visit 2
Visit 4 MB (1)
MACWY (1)
HPV (1)
2 months after visit 3 and also 12 months after
Visit 5 PN23 (1)
HPV (2)
1 month after visit 4





6 months after visit 4 and 4 months after visit 5
Visit 7 MMR (1)
VZ (1)
24 months after BMT, with no immunosuppressant therapy or 
graft versus host disease present, and cell immunity reconsti-
tuted
Visit 8 MMR (2)
VZ (2)
2 months after visit 7
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